Mark Hoerman, MD
Pulmonary Disease · Vidalia, GANPI 1366440984
Payments from drug & device makers
Across 33 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$189
- GSK$133
- Boehringer Ingelheim$69
- Grifols USA, LLC$66
- Insmed, Inc.$63
- Advanced Respiratory, Inc$54
- plus $187 from 8 others
What the payments were for
- Food & beverage$71093%
- Education$527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $189 |
| GSK | 7 | $133 |
| Boehringer Ingelheim | 4 | $69 |
| Grifols USA, LLC | 2 | $66 |
| Insmed, Inc. | 4 | $63 |
| Advanced Respiratory, Inc | 1 | $54 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Amgen | 1 | $34 |
| AbbVie | 2 | $31 |
| Verona Pharma, Inc. | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Eisai Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Biomerieux Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$762 in reported general payments places this provider in the 20th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $275,264 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 261 | $188,725 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $106,037 |
| Breo ElliptaFluticasone/Vilanterol | 191 | $87,422 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $77,092 |
| Ambrisentan | 25 | $53,456 |
| Spiriva RespimatTiotropium Bromide | 77 | $43,927 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 78 | $40,706 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $34,634 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 64 | $33,103 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 47 | $24,753 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 92 | $18,563 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $15,068 |
| Spiriva HandihalerTiotropium Bromide | 26 | $13,351 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 27 | $11,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $133 | $323,137551 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $69 | $109,386202 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $189 | $60,859138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Vidalia
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.